Kyprolis approved for multiple myeloma

(HealthDay) -- Kyprolis (carfilzomib) has been approved by the U.S. Food and Drug Administration to treat certain people with multiple myeloma who have already been given at least two prior therapies.

is a form of cancer that arises from blood plasma, usually starting in the bone marrow, the agency said in a news release. More than 21,000 people in the United States are expected to be diagnosed with the disease this year, and about 10,700 will die from it, the estimates.

Kyprolis has been approved for people treated previously with the anti-cancer drug bortezomib, and an immunomodulatory therapy such as thalidomide.

The most common side effects observed during clinical testing of Kyprolis included fatigue, low blood cell counts, low platelet counts, diarrhea and fever. More serious but less common adverse reactions included heart failure and shortness of breath, the FDA said.

Kyprolis is marketed by San Francisco-based Onyx Pharmaceuticals.

More information: Medline Plus has more about multiple myeloma.

add to favorites email to friend print save as pdf

Related Stories

FDA panel unanimously backs Onyx cancer drug

Jun 21, 2012

(AP) — A federal panel of cancer specialists on Wednesday unanimously recommended approval of an experimental drug from Onyx Pharmaceuticals Inc. for patients with advanced blood cancer.

US focuses on toxic side effects with Onyx drug

Jun 18, 2012

(AP) — The toxic side effects of an experimental cancer drug from Onyx Pharmaceuticals may outweigh its benefits for patients with a type of blood cancer, federal health regulators said Monday.

Perjeta approved for advanced breast cancer

Jun 11, 2012

(HealthDay) -- Perjeta (pertuzumab) has been approved by the U.S. Food and Drug Administration to treat people with HER2-positive late-stage breast cancer, the agency said in a news release.

Recommended for you

Endogenous hormones improve breast cancer risk models

19 hours ago

(HealthDay)—Inclusion of endogenous hormones in prediction models improves prediction of invasive breast cancer risk in postmenopausal women, according to a study published online Aug. 18 in the Journal of ...

Novel oncogenic RET mutation found in small cell lung cancer

20 hours ago

For the first time an oncogenic somatic mutation at amino acid 918 in the RET (rearranged during transfection) protein has been identified in small cell lung cancer (SCLC) tumors and enforced expression of this mutation within ...

User comments